Australia - engelsk - Department of Health (Therapeutic Goods Administration)

go relief pty ltd - eucalyptus oil, quantity: 50 mg/g (equivalent: cineole, qty 35 mg/g); peppermint oil, quantity: 50 mg/g (equivalent: menthol, qty 15 mg/g); wintergreen oil, quantity: 200 mg/g (equivalent: methyl salicylate, qty 180 mg/g); ginger oil, quantity: 100 mg/g - ointment - excipient ingredients: d-alpha-tocopherol; white beeswax; avocado oil - traditionally used in asian medicine to anti-inflammatory/relieve inflammation ; traditionally used in australian indigenous medicine to anti-inflammatory/relieve inflammation ; anti-inflammatory/relieve inflammation ; traditionally used in asian medicine to analgesic/anodyne/relieve pain ; traditionally used in australian indigenous medicine to analgesic/anodyne/relieve pain ; analgesic/anodyne/relieve pain ; decrease/reduce/relieve mild joint aches and pains ; traditionally used in asian medicine to decrease/reduce/relieve mild joint aches and pains ; traditionally used in australian indigenous medicine to decrease/reduce/relieve mild joint aches and pains ; traditionally used in australian indigenous medicine to decrease/reduce/relieve mild rheumatic aches and pains ; traditionally used in asian medicine to decrease/reduce/relieve mild rheumatic aches and pains ; decrease/reduce/relieve mild rheumatic aches and pains ; traditionally used in australian indigenous medicine to decrease/reduce/

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

go-to skincare pty ltd - bemotrizinol, quantity: 25 mg/g; ethylhexyl triazone, quantity: 48 mg/g; diethylamino hydroxybenzoyl hexyl benzoate, quantity: 66 mg/g; tris-biphenyl triazine, quantity: 20 mg/g - cream - excipient ingredients: propanediol; octanohydroxamic acid; xanthan gum; citric acid; sorbic acid; glyceryl caprylate; trihydroxystearin; aloe vera; glyceryl monostearate; octyldodecanol; iron oxide red; potassium hydroxide; iron oxide black; sodium dehydroacetate; purified water; glycerol; jojoba esters; cetostearyl alcohol; potassium cetyl phosphate; iron oxide yellow; tapioca starch; ubidecarenone; salicylic acid; benzyl alcohol; 1,3-butylene glycol; sodium hydroxide; dibasic sodium phosphate; decyl glucoside; terminalia ferdinandiana; fragrance (perfume); d-alpha-tocopherol; beta-tocopherol; delta-tocopherol; gamma-tocopherol; dicaprylyl carbonate; soya oil - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 broad spectrum high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

go-to skin care - bemotrizinol, quantity: 20 mg/g; diethylamino hydroxybenzoyl hexyl benzoate, quantity: 60 mg/g; ethylhexyl triazone, quantity: 35 mg/g; tris-biphenyl triazine, quantity: 20 mg/g - cream - excipient ingredients: purified water; glycerol; propanediol; xanthan gum; glyceryl monostearate; cetostearyl alcohol; ubidecarenone; iron oxide black; iron oxide red; iron oxide yellow; octyldodecanol; jojoba esters; trihydroxystearin; potassium cetyl phosphate; glyceryl caprylate; octanohydroxamic acid; benzyl alcohol; salicylic acid; sodium dehydroacetate; tapioca starch; potassium hydroxide; citric acid; aloe vera; sorbic acid; 1,3-butylene glycol; sodium hydroxide; dibasic sodium phosphate; decyl glucoside; d-alpha-tocopherol; soya oil; beta-tocopherol; delta-tocopherol; gamma-tocopherol; terminalia ferdinandiana; dicaprylyl carbonate; fragrance (perfume) - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 broad spectrum high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Den europeiske union - maltesisk - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunoloġiċi għall-għasafar - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Den europeiske union - estisk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kana - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Den europeiske union - litauisk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - vištiena - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Den europeiske union - litauisk - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunologiniai vaistai - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Den europeiske union - litauisk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - vištiena - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Den europeiske union - latvisk - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunoloģisks aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Den europeiske union - latvisk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - cālis - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.